Purchase Of Non-Controlling Interests	9 Months Ended
Purchase Of Non-Controlling Interests	Mar. 31, 2011
Noncontrolling Interest [Abstract]
Purchase Of Non-Controlling Interests	PURCHASE OF NON-CONTROLLING INTERESTS In August 2010, we purchased all the remaining shares outstanding of PAREXEL International Clinical Research Private Limited from its minority shareholders for approximately $1.6 million, pursuant to a call option. The transaction was accounted for as an equity transaction following the guidance of ASC 810, “Consolidation,” because we controlled and consolidated PAREXEL International Clinical Research Private Limited prior to the transaction.

The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.

+ References+ Details